Mark W Ball1, Brian M Shuch2. 1. Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, Maryland. 2. Institute of Urologic Oncology, UCLA School of Medicine, Los Angeles, California, USA.
Abstract
PURPOSE OF REVIEW: To describe current paradigms for genetic testing, screening, and treatment of patients with inherited kidney cancer syndromes. RECENT FINDINGS: We describe various new aspects of hereditary kidney cancer. Recent data now support that hereditary kidney cancer may account for 5-8% of kidney cancers diagnosed. Methods of testing have evolved including the introduction of multigene next-generation sequencing panels. We continue to learn more about the natural history and management of classic hereditary cancer syndromes. New emerging conditions with lower kidney cancer penetrance have been recognized adding the growing list of syndromes associated with kidney cancer development. The surgical management strategies of enucleation remain however systemic therapy options are being explored both for localized and advanced settings. SUMMARY: Genetic predisposition to kidney cancer is likely more common than once thought. Knowledge of clinical manifestation and genetic testing strategies are needed to properly identify and treat patient and their families.
PURPOSE OF REVIEW: To describe current paradigms for genetic testing, screening, and treatment of patients with inherited kidney cancer syndromes. RECENT FINDINGS: We describe various new aspects of hereditary kidney cancer. Recent data now support that hereditary kidney cancer may account for 5-8% of kidney cancers diagnosed. Methods of testing have evolved including the introduction of multigene next-generation sequencing panels. We continue to learn more about the natural history and management of classic hereditary cancer syndromes. New emerging conditions with lower kidney cancer penetrance have been recognized adding the growing list of syndromes associated with kidney cancer development. The surgical management strategies of enucleation remain however systemic therapy options are being explored both for localized and advanced settings. SUMMARY: Genetic predisposition to kidney cancer is likely more common than once thought. Knowledge of clinical manifestation and genetic testing strategies are needed to properly identify and treat patient and their families.
Authors: Elise Assouad; Said El Hage; Steven Safi; Antonio El Kareh; Elie Mokled; Pascale Salameh Journal: Cancer Causes Control Date: 2021-11-28 Impact factor: 2.506
Authors: Mark W Ball; Julie Y An; Patrick T Gomella; Rabindra Gautam; Christopher J Ricketts; Cathy D Vocke; Laura S Schmidt; Maria J Merino; Ramaprasad Srinivasan; Ashkan A Malayeri; Adam R Metwalli; W Marston Linehan Journal: J Clin Oncol Date: 2020-02-21 Impact factor: 44.544
Authors: Daiki Ueno; Juan C Vasquez; Amrita Sule; Jiayu Liang; Jinny van Doorn; Ranjini Sundaram; Sam Friedman; Randy Caliliw; Shinji Ohtake; Xun Bao; Jing Li; Huihui Ye; Karla Boyd; Rong Rong Huang; Jack Dodson; Paul Boutros; Ranjit S Bindra; Brian Shuch Journal: Oncotarget Date: 2022-09-14